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Abstract
Background: There are currently several concerns about the ways in which people are recruited
to participate in randomised controlled trials, the low acceptance rates among people invited to
participate, and the experiences of trial participants. An information resource about on-going
clinical trials designed for potential and current participants could help overcome some of these
problems.
Methods: We carried out a scoping exercise to explore the desirability and feasibility of
establishing such a resource. We sought the views of a range of people including people who were
considering taking part in a trial, current trial participants, people who had been asked but refused
to participate in a trial, consumer group representatives and researchers who design and conduct
trials.
Results: There was broad-based support for the concept of a centralised information resource for
members of the public about on-going and recently completed clinical trials. Such an information
resource could be based on a database containing standardised information for each trial relating
to the purpose of the trial; the interventions being compared; the implications of participation for
participants; and features indicative of scientific quality and ethical probity. The usefulness of the
database could be enhanced if its search facility could allow people to enter criteria such as a
disease and geographic area and be presented with all the trials relevant to them, and if optional
display formats could allow them to view information in varying levels of detail. Access via the
Internet was considered desirable, with complementary supported access via health information
services. The development of such a resource is technically feasible, but the collation of the
required information would take a significant investment of resources.
Conclusion: A centralised participant oriented information resource about clinical trials could
serve several purposes. A more detailed investigation of its feasibility and exploration of its
potential impacts are required.
Background
The rigorous evaluation of health care interventions
requires potential users of these interventions to partici-
pate in clinical trials to assess their effectiveness. There are
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tion of eligible people who participate in randomised
controlled trials (RCTs) and the experiences of partici-
pants [1,2]. Inadequate information provision is a con-
tributing factor to several of these concerns. For example,
some people who would like to enter RCTs are not invited
to do so, and struggle to identify trials for which they
would be eligible [3]. Problems have been identified with
the quality of information given [4]. Thus some people
who are invited to participate in RCTs do not develop an
adequate understanding to make a well-informed deci-
sion to participate or not [5,6]. People who agree to par-
ticipate in trials sometimes struggle to make sense of their
participation [7], may not know what to do if they iden-
tify questions during the course of the trial, and are often
disappointed at the lack of information they are given
about the progress or results of the trials [8].
An information resource about ongoing clinical trials
designed for potential and current participants could help
overcome some of these problems. It could serve as a
source of additional, semi-independent information for
people who have been invited to participate in trials, and
it could help people to identify trials in which they might
participate. If kept up to date, it could serve as a source of
information about the progress and results of particular
trials.
A number of trial registers have been established in recent
years (for example, metaRegister of Controlled Trials
http://www.controlled-trials.com, UKCCCR National
Register of Cancer Trials http://www.ctu.mrc.ac.uk/ukc
ccr/home.asp), and there has been increasing pressure for
requirements that all clinical trials be registered in the
public domain. [9]. Trial registers are undoubtedly helpful
in terms of getting information about planned, ongoing
and completed trials into the public domain and reducing
the problems associated with underreporting of trials.
However, the current registers are not comprehensive [10-
12]. They were not designed to be easily accessible or use-
ful to general public audiences and none were designed
specifically to meet the information needs of members of
the public as potential or current trial participants. It can
be difficult to identify which registers are appropriate for
particular purposes [12,13], and it is hard to search across
registers because they do not organise and present infor-
mation in a standardised way [3,13].
In this paper we report on a scoping exercise undertaken
for Consumers in NHS Research (now known as
INVOLVE) to assess the desirable features and feasibility
of developing and providing an information resource
about ongoing clinical trials for potential and current par-
ticipants [14].
Methods
We recognised that people who had played different roles
in relation to trials would have different perspectives on
information needs relating to clinical trials. Reflecting
this, we sought information and opinions from a range of
people from across the UK that included: people seeking
to participate in or considering participating in a trial; cur-
rent and recent trial participants; representatives of
national patient interest/support groups; and researchers
involved in the design and conduct of trials. People who
were seeking to participate and considering participating
in a trial were identified through condition-specific con-
sumer networks, in particular the National Association for
the Relief of Paget's Disease (a trial investigating the treat-
ment of Paget's disease was about to start at the time we
conducted this scoping exercise). Current and recent trial
participants were identified at three meetings of health
care consumers and advocates. Representatives of con-
sumer groups were selected from those patient interest/
support groups with a known interest in trials (identified
primarily by Consumers in NHS Research). Researchers
involved in the design and conduct of trials were selected
from the UK MRC trial managers network and individuals
known to the research team. Several of the consumer
advocates and researchers had current or recent personal
experience of participating (or declining to participate) in
clinical trials. We accepted their contributions from the
perspective of trial participants, because the time frame of
our scoping exercise did not permit us to obtain ethics
committee approval to identify and approach current par-
ticipants via trial offices.
We used semi-structured interviews, focus groups and e-
mail discussion lists to explore the kinds of information
that people want and need when considering whether or
not to participate in a particular trial, and the ways they
might access and use this information. We asked people to
discuss the feasibility and appropriateness of 'star rated'
information on the quality of particular aspects of ongo-
ing trials, and the provision of generic guidance about
how to interpret and appraise information about trials.
We also asked researchers and consumer representatives
what they thought made for a good quality trial and what
issues might arise from an attempt to provide standard-
ised information about ongoing randomised clinical trials
in a publicly accessible participant-orientated informa-
tion resource.
We used topic guides to support semi-structured inter-
views and focus group discussions. An example of the
topic guide used with potential trial participants is
included [see Additional file 1]. Most interviews were
audio-taped and transcribed in full. If audio-recording
was not possible, members of the research team took
detailed notes. Analysis of transcripts, discussion notesPage 2 of 6
(page number not for citation purposes)
BMC Health Services Research 2005, 5:39 http://www.biomedcentral.com/1472-6963/5/39and e-mails was carried out using a modified 'charting'
approach [15]: to facilitate the identification of the range
of views about particular issues, the points made by each
participant were summarised under key headings that
reflected the main areas of questioning.
Over the course of the scoping exercise we formally inter-
viewed 25 individuals on a one-to-one basis including:
• nine potential trial participants;
• six representatives from patient interest /support groups;
• nine researchers (including trial principal investigators,
trial managers and a research nurse); and
• one pharmaceutical/medical devices industry
representative.
In addition, the views of 24 consumer advocates were elic-
ited in focus groups held at national meetings of consum-
ers and advocates, and nine consumer representatives
contributed comments via e-mail. Several of the con-
sumer advocates and researchers had personal experience
of participating (or declining to participate) in clinical
trials.
Results
Information elements required by potential trial 
participants
Our informants identified a range of information needs of
potential trial participants. We grouped these into the fol-
lowing categories: (a) the interventions being compared;
(b) the implications of trial participation for participants;
(c) the scientific or methodological quality of a trial; (d)
the ethical probity and governance of a trial; and (e) con-
tact details (Figure 1).
The features identified as desirable for a centralised information resource about randomised controlled trialsFigure 1
The features identified as desirable for a centralised information resource about randomised controlled trials.
INFORMATION ELEMENTS
Scientific/ methodological quality: Assurance that the trial protocol
had been independently peer reviewed; assurance that the trial was 
well designed to generate robust knowledge.
Interventions being compared: What processes they involve; how 
they ought to work; hoped for benefits; known effects/ side effects.
Implications for participants:  Extra visits or tests; How long the trial
would run for; Length of follow-up for individual participants;
description of how and when they could withdraw.
Importance of the trial: What knowledge it would generate and the
difference that knowledge could make in practice.
Ethical probity & governance: Assurance that the trial had been
approved by an independent ethics committee; assurance that
appropriate structures and processes were in place to protect
interests of participants.
Contact details: Information about who to contact with different
types of query/concern about a particular trial.




AIDS TO INFORMATION APPRAISAL
Information about trials in general:  purpose
of trials; key features of trials (including
randomisation); glossary of terms.
Self-appraisal guide:  To help people appraise
the quality of particular trials for themselves.
KEY DESIGN FEATURES
Sophisticated search facility: to allow people to retrieve
information on trials that fulfilled their search criteria.
Options to view information in varying levels of detail
Use of different media types: permits incorporation of video
clips etc.Page 3 of 6
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There was a consensus that potential trial participants
need to know about the 'new' intervention being tested,
its potential risks, and how it is known to compare with
the current "standard" intervention and any other inter-
ventions with which it is compared in the trial. Informa-
tion about the availability of relevant interventions
outwith the trial was also mentioned as important.
Implications for participants
Information needs relating to implications for partici-
pants included practical issues such as the timescales for
the trial interventions and follow-up, and the rationale
for, and number of extra visits or investigations associated
with the trial. Several informants highlighted the need for
information about whether and how people could with-
draw from or join the trial at a later date. They also
thought that participants should be told whether or how
they could gain access to data about their own outcomes
and the trial findings, and about whether and how partic-
ipants would be told if a trial was stopped early for any
reason.
Scientific or methodological quality, and ethical probity and 
governance
There was a consensus that people should be able to be
confident about the quality of any trial they might agree
to participate in, but it was widely recognised that rela-
tively few people would currently be able to judge the sci-
entific quality or ethical probity of a trial for themselves
on the basis of the information they are typically given for
recruitment purposes. The provision of information
about key features of trial quality (and/or about quality
assessment) was thought desirable for a centralised
resource.
Contact details
Several respondents from all categories mentioned that
potential trial participants might benefit from the option
to talk to someone before deciding whether or not to par-
ticipate in a trial, and possibly also during the trial. The
case was regularly made that two-way interaction was key
to understanding information, as any misconceptions
could be corrected and personal concerns could be
addressed. For people who had been invited to participate
in a particular trial, the options suggested were:
• having a chance to speak with a member of the trial team
(preferably someone who is not related directly to a per-
son's normal care) – someone who can explain things like
randomisation;
• having a chance to talk to an independent person (i.e.
someone not associated with the trial) e.g. GP, consumer
advocate, voluntary health organisations, advice services;
and
• having contact details, so know whom to contact if con-
cerned about anything while participating in the trial.
People who were themselves looking for trials in which
they might participate would be likely to need:
• contact details for initial enquiries about the specific
trial and (possibly subsequently) local recruiting centres/
clinicians; and possibly
• an information helpline staffed by people who could
offer general information, answer general questions about
trials, and help explain information provided about spe-
cific trials.
However, the capacity of trialists or trial centres to handle
unsolicited enquiries was limited, they might be reluctant
to have their contact details 'advertised' in the context of
an information resource that promised help to people
identify trials in which they might participate.
Aids to information appraisal
As indicated in the methods section, we explored two
approaches that might help people evaluate information
about trials and assess their quality: (a) a quality or "star"
rating scheme in which key features of trials were allo-
cated one- to three- star ratings; and (b) a guide to help
people appraise trials for themselves.
Informants registered some strongly felt concerns about
the quality ratings option. These included doubts about
the feasibility of producing valid and reliable ratings
across a diverse range of trials, and fears that particular rat-
ings were likely to be contested by trial sponsors and trial-
ists, which could create a lot of 'hassle' and work for the
resource producers.
Despite the limitations of a quality ratings scheme, there
was general agreement that it would be useful to indicate
that key quality assurance features were in place for partic-
ular trials. The most obvious features suggested were that
a trial had been through an independent peer review proc-
ess (a check on scientific quality) and that it had been
assessed and approved by an independent ethics commit-
tee (a check on ethical probity).
There was widespread support for the provision of a gen-
eral information section within any centralised resource
that could: explain the purpose of clinical trials; highlight
key features and indicate points to look out for in clinical
trials; provide a glossary of commonly used terms; and
identify links to relevant organisations. The inclusion of aPage 4 of 6
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themselves was also thought appropriate. This guide
could be based on existing checklists developed for peer
reviewers, ethics committees and consumer representa-
tives who appraise trials, but modified for more general
public use.
Key design features of a centralised resource
All informants supported the basic concept of a central-
ised information resource about clinical trials. This could
be built using a database structure with a standard set of
information elements for each trial reflecting the key areas
outlined above. Respondents identified a variety of design
features that could potentially enhance the usefulness of
the information within the resource, including:
• A sophisticated search facility that would allow people
to enter their personal details (e.g. health condition, age,
gender, geographical location etc), and retrieve informa-
tion on trials that fulfilled their search criteria.
• Options to view particular types of information in vary-
ing levels of detail.
• The use of a variety of media within or as a complement
to the resource (for example, diagrams or video-clips to
illustrate and explain trial procedures or the interventions
being compared in particular trials
Potential models for providing a centralised information 
resource
There was widespread support for the provision of this
centralised information resource on the Internet, but a
clear recognition that some people would not be able to
access the information effectively via this route. Opportu-
nities for supported access via outlets in health care set-
tings, public libraries or other community centres would
also be useful. Health information services might usefully
serve as valuable 'intermediaries', adding value to the
resource by helping people to appraise the information
and interpret it for their own use.
Discussion
One of the strengths of our study is that we canvassed
views from a range of perspectives. We identified a broad-
base of support for the concept of a centralised, publicly
accessible, participant-oriented information resource
about ongoing clinical trials. We also identified several
concrete suggestions for the content and design of such a
resource. However, time constraints prevented us from
exploring the views of a larger sample of people, and from
considering the issues we identified in more depth. We
acknowledge in particular that further research is needed
to explore the opinions of a wider spectrum of the 'general
public' as potential users of a centralised resource for
information about clinical trials, and to consider the
potential implications of presenting particular elements
of information and in particular ways. We also acknowl-
edge that the potential trial participants interviewed for
this study were mostly people with a chronic condition.
Their perspectives may differ from potential trial partici-
pants with acute health problems. However, individuals
with acute conditions were canvassed for their views as
current or recent trial participants. We do not claim to
have identified all possible information requirements, but
are confident that we have identified the main ones.
In theory, a centralised information resource about clini-
cal trials would have two main audiences in terms of trial
participants: those who have been invited to participate in
a trial and want to find out more about it, and those who
have not been invited to participate in a trial, but would
like to identify any ongoing trials for which they might be
eligible. If the resource included updated reports on trial
progress, it may also be useful to a third group of people
who are currently participating in trials who want more
information about the trials in which they are
participating
It is unclear whether and to what extent a centralised
information resource would achieve the desired aims of
improving recruitment rates, and people's experiences of
information provision relating to trial recruitment and
participation, nor whether it would have any unwanted
effects. It is not clear to what extent a publicly accessible
resource might increase demand for participation in trials,
nor what the implications of such demands might be. At
the moment, some health care providers are not in a posi-
tion to offer trial participation to their service users.
Increased public awareness of particular trials might place
a variety of extra burdens on health care systems, for
example if patients start demanding access to particular
trials and/or changing health care providers in order to
gain access to them.
Other potential disadvantages of making information
about trials more easily accessible should be explored. For
example, breaches of privacy might become a problem if
the knowledge that someone is eligible to participate in a
particular trial (which is often readily obtained by third
parties who observe markers on medical records or wit-
ness the receipt of mailings from a trial team) could
quickly lead to the revelation of information about per-
sonal health status or health care experiences because trial
eligibility criteria would be easily ascertained. Public
access to trial progress reports might, depending on the
nature of information provided, influence people's self-
reporting of outcome status and willingness to continue
to participate in a trial. Issues such as these require further
consideration and investigation.Page 5 of 6
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engine and the features identified above as desirable are
technologically feasible, there are several potential barri-
ers to the development of a participant-oriented central
information resource about clinical trials. Current trial
registers do not contain all the information elements that
potential participants might find useful. The process of
gathering, checking and updating the requisite informa-
tion would be logistically challenging and time consum-
ing, and would require considerable and sustained
investment. Any attempt to include trial progress reports
to the database would significantly add to the logistical
challenges. However, recent trends towards increasing dis-
closure of information about trials, including commit-
ments to openness from some pharmaceutical
companies, will facilitate the acquisition of relevant
information.
Conclusion
A centralised participant-oriented information resource
about randomised trials could offer many benefits. The
development of such a resource would require considera-
ble investment, but the support for the basic concept that
is evident among trial participants, consumer advocates
and trialists suggest that it warrants further investigation
and evaluation.
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